Sugi Predict

Sugi Predict / Compounds / SCHEMBL4469460

SCHEMBL4469460

SCHEMBL4469460

NC(=O)c1c(NC2CCN(S(=O)(=O)c3ccccc3)C2)sc(C(=O)c2cc(-c3ccccc3)no2)c1N

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 5/20 0.40
▸ CHRM4 P08173 1/20 0.39
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.35
▸ ATR Q13535 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4466084 0.92 USP30 (0.41) USP30SMN1; SMN2PTPN1LMNATP53
SCHEMBL4467806 0.92 JAK3 (0.41) USP30CHRM4SMN1; SMN2NPSR1PTPN1
SCHEMBL4466293 0.88 USP30 (0.44) USP30CHRM4MEN1KMT2AUSP2
SCHEMBL4474610 0.86 USP30 (0.43) USP30SMN1; SMN2LMNATP53MAPT
SCHEMBL3816591 0.83 LMNA (0.40) USP30MEN1KMT2ASMN1; SMN2NPSR1
SCHEMBL3816399 0.80 CHEK1 (0.41) USP30LMNATP53MAPT
SCHEMBL4485824 0.79 USP30 (0.45) USP30SMN1; SMN2ALDH1A1MAPT
SCHEMBL4473863 0.79 USP30 (0.45) USP30SMN1; SMN2NPSR1ALDH1A1MAPT
SCHEMBL3818041 0.78 KDM4E (0.37) USP30MEN1KMT2ALMNATP53
SCHEMBL4472754 0.77 KDM4E (0.41) USP30MEN1KMT2ASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A USP30 2232/4885CHRM4 3626/4885MEN1 2737/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A USP30 2232/4885CHRM4 3626/4885MEN1 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.